Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment.

Daniel P HurkmansJeroen G H P VerhoevenKitty de LeurKarin BoerArjen JoosseCarla C BaanJan H von der ThüsenRon H N van SchaikRon H J MathijssenAstrid A M van der VeldtDennis A Hesselink

Published in: Journal for immunotherapy of cancer (2019)

Clinicians prescribing ICIs should be aware that SOT recipients are at risk of transplant rejection as a result of T cell activation. Dd-cfDNA is a sensitive biomarker and should be further studied for early detection of transplant rejection. Immunological analysis of the kidney explant showed marked graft infiltration with alloreactive PD-1+ cytotoxic T cells that were saturated with nivolumab.

Keyphrases

primary care
palliative care
emergency department
kidney transplantation
combination therapy